Neumora Therapeutics, Inc.

Neumora Therapeutics is a clinical biopharmaceutical company developing treatments for brain diseases, as well as major depression and other mental and neurological disorders of the brain.

Brain diseases collectively represent one of the largest areas of unmet medical needs worldwide, affecting more than 1.5 billion patients. This is a huge market with very low competition among pharmaceutical companies.

The company plans an IPO of $250 million, which will be directed towards further research and increased sales.